1,518,805 Shares in Repligen Corporation $RGEN Purchased by Maverick Capital Ltd.

Maverick Capital Ltd. purchased a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the first quarter, Holdings Channel.com reports. The firm purchased 1,518,805 shares of the biotechnology company’s stock, valued at approximately $178,946,000. Repligen accounts for about 2.1% of Maverick Capital Ltd.’s holdings, making the stock its 22nd largest holding.

Several other institutional investors and hedge funds have also recently modified their holdings of RGEN. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen during the third quarter valued at approximately $29,000. Bayforest Capital Ltd bought a new position in Repligen during the 4th quarter valued at $32,000. Rachor Investment Advisory Services LLC purchased a new position in Repligen during the 4th quarter worth $33,000. Los Angeles Capital Management LLC bought a new stake in shares of Repligen in the 4th quarter worth $36,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

Shares of RGEN opened at $131.06 on Tuesday. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $175.77. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The stock’s fifty day moving average price is $132.21 and its two-hundred day moving average price is $132.05. The firm has a market cap of $7.39 billion, a PE ratio of 145.62, a PEG ratio of 2.54 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.10. The company had revenue of $194.25 million during the quarter, compared to analyst estimates of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, equities research analysts forecast that Repligen Corporation will post 1.99 EPS for the current year.

Insider Activity at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of recent analyst reports. Jefferies Financial Group reaffirmed a “hold” rating and issued a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. HSBC decreased their price target on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Royal Bank Of Canada assumed coverage on Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective for the company. Roth Capital initiated coverage on Repligen in a research note on Friday, April 17th. They set a “buy” rating and a $160.00 target price on the stock. Finally, Wolfe Research assumed coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.36.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.